Coronavirus Vaccines Latest Updates: Spiritual Solution for COVID-19
As per WHO, at least 13 experimental COVID-19 vaccines are currently being tested in humans and more than 120 candidates are in earlier stages of development.
Coronavirus vaccines latest updates: The whole world is facing a serious problems with coronavirus outbreak. The readers will know the status of vaccine development by the scientist community to fight the pandemic worldwide. know the Coronavirus (Covid-19) vaccines status latest updates
Coronavirus Vaccines Latest Updates: HIGHLIGHTS
- The preventive vaccine developed by Nigerian Universities’ Scientists to come out in at least 18 months commercially
- WHO’s latest data shows as many as 13 experimental coronavirus vaccine are currently being tested in humans, but more than 100 organizations are active
- Vaccines developed by Moderna Inc, Sinovac Biotech-China and UK Oxford University-AstraZeneca to enter late-stage trials in July
- WHO announced stopping of the Solidarity Trial of the hydroxychloroquine (HCQ) arm to find an effective COVID-19 treatment
- “off level” use medicines are the licensed ones but not approved by national medicine regulatory authority.
- India launched two medicines for the cure of COVID-19 treatment yet to be proved on a mass scale
What is a vaccine?
A vaccine is preventive and is designed to protect a person before exposer to a virus — in the present case, SARS-CoV-2, the virus to cause COVID-19. A vaccine works on the immune system as a Trusted Source to recognize and attack the virus when it attacks it. The vaccine protects the vaccinated person from Viruses infection. It also means vaccinated people cannot pass the virus to others, in other words, it improves herd immunity.
Experimental COVID-19 vaccines being tested
As per the World Health Organization (WHO), at least 13 experimental COVID-19 vaccines are currently being tested in humans and more than 120 candidates are in earlier stages of development.
Many other institutions are working on potential vaccines for SARS-CoV-2, with several backed by the nonprofit Coalition for Epidemic Preparedness Innovations (CEPI). Today more than 100 projects Trusted Source around the world centered on the development of a vaccine for the coronavirus. Thirteen candidate vaccines were being tested in clinical trials in people. Large-scale testing could begin in July 2020 with a vaccine potentially available by January 2021. Many others indicate the more likely timeline in the summer or fall of 2021.
Projects on COVID-19 Vaccine
Coronavirus Vaccines Latest Updates: There are a number of vaccines developed by Moderna Inc, Sinovac Biotech China, and UK’s Oxford-AstraZeneca to move into late-stage testing in the month of July. Perhaps everything will go well, and the world may have a jab for emergency use by November. Britain and the US have spent millions of dollars into various vaccine candidates, including one being developed by Oxford University and manufactured by AstraZeneca.
- Moderna company began testing its messenger RNA (mRNA) vaccine in a phase I clinical trial in Seattle, Washington in March. In mid-May, the company’s vaccine produced antibodies in all 45 trial participants healthy volunteers, ages 18 to 55. The company has experience of developing other mRNA vaccines before and show their platform safe, therefore the company can skip certain animal testing for this specific vaccine. In early May, the company got FDA’s permission to start a phase II study of its vaccine. The company is expected to begin a phase III clinical trial in July. The FDA agreed to fast-track regulatory review of this vaccine upon its success in the phase III clinical trial.
- Inovio company had already been working on a DNA vaccine for MERS, which is caused by another coronavirus well before COVID-19. Due to this experience, the company quickly developed a potential vaccine for SARS-CoV-2. The company enrolled 40 healthy volunteers in its phase I clinical trial in late April. Inivio is to carry out phase II/III clinical trial in the summer.
- The University of Oxford in England began Phase I/II trials in April to assess the safety and immune response in over 1,000 healthy volunteers aged 18 to 55 years across several trial centers in southern England.
- The University of Oxford moves for 2,000 volunteers Phase II trials in Brazil. The trial moves to Phase III with a larger population of 10,000 participants in the UK and 30,000 participants in the US. According to Oxford officials, the potential vaccine has good chances of success and be available as early as September. The vaccine uses a modified virus to trigger the immune system. The University and AstraZeneca tied up an agreement on April 30 for the global development and distribution of vaccines.
- China National Biotec Group (CNBG), known as Sinopharm, has claimed that its experimental coronavirus vaccine has successfully triggered antibodies in clinical trials. Sinopharm initiated clinical trials in April involving 1,120 healthy participants aged between 18 and 59. Now the company plans late-stage human trials in foreign countries. The inactivated vaccine to be called CoronaVac induced neutralizing antibodies in over 90 percent of the 600 healthy volunteers in phase 2.
- The University of Queensland in Australia researchers are working hard on the development of a vaccine by growing viral proteins in cell cultures. They had begun preclinical testing stages in early April.
- Pharmaceutical firms Johnson & Johnson and Sanofi are also working on developing a vaccine. Johnson & Johnson reported on June 10 about their program of beginning early-stage human clinical trials in late July.
- Pfizer has collaborated with a German company to develop a vaccine. Their initial clinical trial with 200 participants was given the green light in late April. The two companies began human testing in the United States in early May.
- On Friday, Nigerian Universities’ Scientists recently claimed about their discovery of a coronavirus vaccine to prevent the SARS-CoV-2 virus infection. Leader of the research team Dr. Oladipo Kolawole, a specialist in Medical Virology, Immunology, and Bioinformatics, at Adeleke University, Ede in Osun said that the vaccine was being developed locally in Africa for Africans. It would take a minimum of 18 months to be available to the public for widespread use after lot of analysis and trials as well as approvals by medical authorities. It was reaffirmed, the vaccine is real and has been validated several times. It is targeted at Africans but be effective for other races.
What are Clinical trial stages?
- Phase I. The experimental drug is given to a small number of healthy people and the patients to look for side effects and figure out the best dose.
- Phase II. The experimental drug is given to hundreds of people with disease to reaffirm efficacy and side effects on bigger lot if uncaught in initial testing.
- Phase III. The experimental drug is to several hundred to 3,000 people. A similar number of people take a placebo, or inactive compound. This is randomized trial from 1 to 4 years. It delivers the best evidence of how the drug works and the most noticeable side effects.
- Phase IV. The approved drugs undergo continued monitoring for any other side effects, especially serious or long-term ones.
Are any safe pharmaceutical products available for COVID-19 treatment?
World Health Organization (WHO) in its Scientific brief published on 31 March 2020 titled as Off-label use of medicines for COVID-19 has mentioned that no pharmaceutical products are safe for COVID-19 treatment. It says that many medicines have been suggested so far and many are now being studied in clinical trials sponsored by WHO and participating countries.
What is off level use medicine?
Coronavirus Vaccines Latest Updates: The readers should know “off level” use medicines are the licensed ones but not approved by national medicine regulatory authority. WHO says doctors prescribe off level medicines to COVID-19 patients but they should decide for each individual case.
What should one do in emergency?
Coronavirus Vaccines Latest Updates: WHO suggests applying an ethical approach during emergencies when clinical trials are neither complete nor can be completed in a short time, the doctors may offer experimental interventions to the patients. Such decision to offer unproven or experimental treatment will be on mutual consent basis between the doctor and individual patient. Proper records should be maintained of such cases and if the outcome is promising the treatment should be studied in context of formal clinical trials to fix benefits, efficacy, risks, and safety.
What is the COVID 19 status in India?
Two drugs have come out in India on Saturday and Sunday. We shall see details as under.
How effective will be Glenmark’s first antiviral drug?
Coronavirus Vaccines Latest Updates: Drug manufacturer Glenmark Pharmaceuticals on Saturday has launched the first antiviral drug in India, Favipiravir, with a brand name FabiFlu. Glenmark got consent for manufacturing and marketing as part of an accelerated approval process, in the emergency of the COVID-19 outbreak in India.
- Restricted use approval entails responsible medication usage. The hospital will take signed informed consent before treatment initiation from the patient.
- This medicine is good enough for mild to moderate COVID-19 symptoms patients with co-morbid conditions such as diabetes and heart disease.
- Antiviral drug Favipiravir is capable to reduce viral load rapidly within four days.
- This drug was approved in Japan in 2014 for the treatment of novel or re-emerging influenza virus infections.
- It’s clinical trials have shown 88 percent improvement in mild to moderate COVID-19 cases.
Second drug Covifor launched by Hetro drugmaker in India
Drug making company Hetero on Sunday got the DGCI nod to launch an antiviral Remdesivir for treatment of COVID-19. The new drug is termed as Covifor. It is second such drug to enter the Indian market after Fabiflu by Glenmark, which came on Saturday.
Trials for drugs and vaccines helped in containing and curing coronavirus. The facts known about Covifor are:-
- The drug is 100 mg in an injectable form to be administered intravenously in a hospital under the supervision of a healthcare professional. This drug cannot be taken at home.
- The company will make sure to maintain enough stock to cater to the present needs.
- Covifor would cost between Rs 5,000 to Rs 6,000 per dose.
- Covifor will cost about 30,000 per patient for the COVID-19 treatment, six dozes of the medicine will be given.
Hydroxychloroquine (HCQS) Solidarity Trial stopped
ON 17 June 2020 WHO announced stopping of the Solidarity Trial of the hydroxychloroquine (HCQ) arm to find an effective COVID-19 treatment. The French Discovery trial data and the UK’s Recovery trial both showed that hydroxychloroquine does not result in the reduction of mortality of hospitalized COVID-19 patients when compared with standard of care. However, India is continuing to use this medicine for preventive measures and mostly the results have been reported to be successful.
Spiritual Options for COVID-19 (Coronavirus) Treatment
The world is full of sorrows and the coronavirus outbreak is its burning example. It is always said that this is the outcome of the past deed of mankind. The fact is that mankind can not do anything on its own. Creative Power is the prime actor behind every action in this universe. The human being must understand all this manipulative act of the Creative Power Maya by coming in the refuge of Enlightened Saint Rampal Ji Maharaj and Take Initiation from him to achieve salvation. The liberated soul will go to Satlok and will never take rebirth.
S A NEWS